Hugel, Inc. (KOSDAQ:145020)
South Korea
· Delayed Price · Currency is KRW 297,000
+2,500 (0.85%)
Sep 29, 2025, 3:30 PM KST
Hugel Revenue
Hugel had revenue of 110.26B KRW in the quarter ending June 30, 2025, with 15.55% growth. This brings the company's revenue in the last twelve months to 403.40B, up 17.44% year-over-year. In the year 2024, Hugel had annual revenue of 373.05B with 16.69% growth.
Revenue (ttm)
403.40B
Revenue Growth
+17.44%
P/S Ratio
7.95
Revenue / Employee
684.89M
Employees
589
Market Cap
3,206.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | 211.04B | 6.47B | 3.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| LigaChem Biosciences | 148.28B |